Cinclus Pharma Holding Past Earnings Performance
Past criteria checks 0/6
Cinclus Pharma Holding's earnings have been declining at an average annual rate of -13.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been declining at an average rate of 27.8% per year.
Key information
-13.1%
Earnings growth rate
-4.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | -27.8% |
| Return on equity | -26.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Cinclus Pharma Holding makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -158 | 36 | 117 |
| 30 Jun 24 | 0 | -183 | 37 | 139 |
| 31 Mar 24 | 3 | -203 | 33 | 158 |
| 31 Dec 23 | 6 | -215 | 40 | 167 |
| 31 Dec 22 | 11 | -249 | 64 | 157 |
Quality Earnings: CINPHA is currently unprofitable.
Growing Profit Margin: CINPHA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CINPHA's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CINPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CINPHA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (8.9%).
Return on Equity
High ROE: CINPHA has a negative Return on Equity (-26.05%), as it is currently unprofitable.